Bruker Announces Integrated Microbiology Workflow For MALDI Biotyper Microbial Identification & BD Phoenix TM Antibiotic Susc...
08 May 2011 - 9:00PM
Business Wire
At the 21st Annual Meeting of the European Society of Clinical
Microbiology and Infectious Diseases (www.congrex.ch/ECCMID2011),
Bruker announced the successful completion of an integrated
workflow using the Bruker MALDI Biotyper for microbial
identification (ID) from cultures, and the BD Phoenix™
system for antibiotic susceptibility testing (AST). The ID and AST
systems are integrated via the BD EpiCenter™ data management
system.
The seamless workflow integration has been validated at a number
of pilot sites in Europe and in the US, including public and
private laboratories such as Dynacare (Milwaukee, Wisconsin),
Klinikum Bayreuth (Germany), Synlab Weiden (Germany), Synlab
Augsburg (Germany) and the Vatican Hospital (Rome, Italy). The
integrated workflow begins with ordering the MALDI Biotyper
ID and BD Phoenix AST using the customer’s Laboratory Information
System (LIS). The order is automatically transferred to the BD
EpiCenter™ middleware and can be used for worklist management.
Barcode labels containing the laboratory accession and isolate
number can be automatically printed for the BD Phoenix and MALDI
Biotyper samples. The sample location on the MALDI
Biotyper plate is mapped using a pre-printed template and BD
EpiCenter barcode labels. The barcodes are scanned into the
MALDI Biotyper software for accurate specimen tracking. The
AST and ID samples are then each processed according to their
respective protocols.
Upon completion of the microbial ID, the MALDI Biotyper
results and confidence values are automatically transferred to BD
EpiCenter over a network interface, and the ID is matched to the
AST results produced by BD Phoenix. All results are analyzed by the
BD Xpert system for quality assurance and alerting. Completed
results are reviewed and released for review by the clinicians and
subsequently to the LIS.
Bruker is also working with BD Diagnostics on an integrated
blood culture workflow, using the BD BACTEC™ blood culture system,
the Bruker MALDI SepsiTyper Kit for sample preparation
directly from positive BD blood culture bottles prior to rapid
MALDI Biotyper ID.
“Detecting known antimicrobial resistance, and, more
importantly, unknown or emerging resistance is a growing concern
for laboratories,” said Professor Anne Simon from Saint-Luc
University Hospital (UCL) in Brussels, Belgium. “For nine years, we
have used the BD Phoenix System to determine antimicrobial
resistance using its resistance marker detection capability. With
the addition of Bruker’s MALDI Biotyper, integrated via the BD
EpiCenter data management system, we can now rapidly and accurately
identify a broad spectrum of microorganisms, which enhances our
ability to provide critical results to clinicians that help improve
patient treatment and outcomes.”
“We are very pleased to see that after six months of
collaborating with Bruker, a number of pilot sites around the world
have implemented this integrated solution successfully,” said Jamie
Condie, Vice President and General Manager, Infectious Disease, BD
Diagnostics – Diagnostic Systems. “It demonstrates that
microbiology laboratories will find value in the combination of our
two capabilities, which together can help enhance clinical
decision-making and enhance laboratory efficiency.”
Frank Laukien, Ph.D., President and CEO of Bruker Corporation,
explained further: “For Europe, it is important to combine the
MALDI Biotyper with an automated AST system, which is
compatible with the European Committee on Antimicrobial
Susceptibility Testing, known as EUCAST. The combination of the
MALDI Biotyper and BD Phoenix thus provides customers with
the most advanced microbial ID system integrated with a
EUCAST-compatible AST system. Bruker is committed to the Open
Microbiology Consortium concepts of open interfaces, and of making
its systems compatible with microbiology products from other
vendors in order to provide the most advanced and cost-effective
solutions to microbiology customers worldwide.”
About the MALDI Biotyper and Bruker Corporation
Bruker’s proprietary MALDI Biotyper solution enables molecular
identification, taxonomical classification or dereplication of
microorganisms like bacteria, yeasts and fungi. Classification and
identification of microorganisms is achieved reliably and quickly
using proteomic fingerprinting by high-throughput MALDI-TOF mass
spectrometry. Applications include clinical routine microbial
identification, environmental and pharmaceutical analysis,
taxonomical research, food and consumer product processing and
quality control, as well as marine microbiology. Bruker’s robust
MALDI Biotyper method requires minimal sample preparation efforts
and offers low consumables cost per sample. The MALDI Biotyper is
available in a research-use-only version, as well as in an IVD-CE
version according to EU directive EC/98/79 in certain European
countries. The MALDI SepsiTyper Kit is presently for research use
only. For more information, please visit
www.bdal.com/maldibiotyper
For more information about Bruker Corporation (NASDAQ: BRKR),
please visit www.bruker.com.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024